These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27473264)

  • 1. T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin.
    Raspollini MR; Luque RJ; Menendez CL; Bollito E; Brunelli M; Martignoni G; Montironi R; Cheng L; Blanca A; Baroni G; Minervini A; Lopez-Beltran A
    Hum Pathol; 2016 Nov; 57():78-84. PubMed ID: 27473264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
    Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
    Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A proposed score for assessing progression in pT1 high-grade urothelial carcinoma of the bladder.
    Raspollini MR; Minervini A; Lapini A; Lanzi F; Rotellini M; Baroni G; Carini M
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):218-27. PubMed ID: 22820663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973).
    March-Villalba JA; Ramos-Soler D; Soriano-Sarrió P; Hervás-Marín D; Martínez-García L; Martínez-Jabaloyas JM
    Urol Oncol; 2019 Feb; 37(2):158-165. PubMed ID: 30446453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma.
    Breyer J; Gierth M; Shalekenov S; Aziz A; Schäfer J; Burger M; Denzinger S; Hofstädter F; Giedl C; Otto W
    World J Urol; 2016 May; 34(5):709-16. PubMed ID: 26394624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.
    Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC
    Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of survivin and DNA topoisomerase IIα in diffuse and anaplastic astrocytomas.
    Varughese RK; Skjulsvik AJ; Torp SH
    Pathol Res Pract; 2017 Apr; 213(4):339-347. PubMed ID: 28214203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sphingosine-1-phosphate receptor 1 (S1PR1) expression in non-muscle invasive urothelial carcinoma: Association with poor clinical outcome and potential therapeutic target.
    Go H; Kim PJ; Jeon YK; Cho YM; Kim K; Park BH; Ku JY
    Eur J Cancer; 2015 Sep; 51(14):1937-45. PubMed ID: 26238015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
    Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
    Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions.
    Shi J; Liu H; Wilkerson M; Huang Y; Meschter S; Dupree W; Schuerch C; Lin F
    Hum Pathol; 2007 Sep; 38(9):1335-44. PubMed ID: 17512033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
    Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
    Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma.
    Kucukgoz Gulec U; Gumurdulu D; Guzel AB; Paydas S; Seydaoglu G; Acikalin A; Khatib G; Zeren H; Vardar MA; Altintas A
    Arch Gynecol Obstet; 2014 Feb; 289(2):393-8. PubMed ID: 23974278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder.
    Yin W; Chen N; Zhang Y; Zeng H; Chen X; He Y; Wang X; Zhou Q
    Mod Pathol; 2006 Nov; 19(11):1487-97. PubMed ID: 16892011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aurora-A/STK-15 is differentially expressed in the micropapillary variant of bladder cancer.
    Compérat E; Roupret M; Conort P; Chartier-Kastler E; Bitker MO; Richard F; Capron F; Haertig A; Cussenot O; Camparo P
    Urol Int; 2009; 82(3):312-7. PubMed ID: 19440020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.
    Klaassen Z; Kamat AM; Kassouf W; Gontero P; Villavicencio H; Bellmunt J; van Rhijn BWG; Hartmann A; Catto JWF; Kulkarni GS
    Eur Urol; 2018 Nov; 74(5):597-608. PubMed ID: 30017405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder.
    Reis LO; Taheri D; Chaux A; Guner G; Mendoza Rodriguez MA; Bivalacqua TJ; Schoenberg MP; Epstein JI; Netto GJ
    Hum Pathol; 2016 Jan; 47(1):20-5. PubMed ID: 26520419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEx C, and p16INK4a/ProEx C in cervical squamous intraepithelial lesions.
    Boucher J; Anku-Bertholet C; Temmar R; Pelmus M
    Hum Pathol; 2009 Jun; 40(6):904-5; author reply 905-6. PubMed ID: 19442790
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of different p16 immunostaining methods and the prognostic role of p16/Ki-67 combined expression in non-muscle invasive bladder cancers.
    Özyalvaçli G; Özyalvaçli ME; Astarci HM; Boran Ç; Yeşil C; Üyetürk U; Aktaș G
    Pol J Pathol; 2015 Mar; 66(1):57-66. PubMed ID: 26017881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Use of Tumor Markers for the Detection and Prognosis of Bladder Carcinoma: A Comparison of CD44, Cytokeratin 20 and Survivin.
    Yikilmaz TN; Dirim A; Ayva ES; Ozdemir H; Ozkardes H
    Urol J; 2016 Jun; 13(3):2677-83. PubMed ID: 27351322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.